Amorfix Chief Scientific Officer receives Genome BC Award for Scientific Excellence
TSX: AMF
TORONTO, April 17, 2012 /CNW/ - Amorfix Life Sciences Ltd. announces that its Chief Scientific Officer, Director and Company founder, Dr. Neil Cashman, has been awarded the 2012 Genome BC Award for Scientific Excellence. This award is presented annually by Genome BC to recognize individuals who have made outstanding contributions to the development of British Columbia's life sciences industry across all sectors which are critical to the economic future of the province and country. Dr. Cashman will receive the award at the Life Sciences BC annual awards gala on April 19, 2012 in Vancouver, BC.
Dr. Cashman is an internationally recognized expert in misfolded protein diseases and the lead inventor of the ProMIS™ discovery technology which is exclusively licensed to Amorfix and being used to identify disease specific epitopes for new therapeutic targets. Amorfix recently announced success in developing antibodies that only bind and kill ovarian tumor cells but do not bind to normal ovarian cells, validating the value of the ProMIS discovery technology.
"We are very pleased to have such a creative force as our Chief Scientific Officer and we are grateful to him for the many contributions he continues to make to our development programs", said Dr. Robert Gundel, Amorfix President and Chief Executive Officer. "With Neil's scientific expertise and guidance, Amorfix is developing an innovative product pipeline of diagnostics and therapeutics that could significantly help patients and their families suffering from diseases such as ALS, Alzheimer's disease and cancer. We congratulate Neil on this well deserved honour and award."
About Amorfix
Amorfix Life Sciences Ltd. (TSX: AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
ProMIS™ and Epitope Protection™ are trademarks of Amorfix Life Sciences Ltd.
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
[email protected]
Janet Clennett
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899
[email protected]
Share this article